Loading...

Home
ETF
06618

06618

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

06618 News

BofAS Maintains JD HEALTH's Target Price at HKD75 and Reiterates Buy Rating, Increases Revenue Growth Projection

M Stanley Reduces JD HEALTH's Target Price to HKD66 and Adjusts EPS Projections Downward

Nomura: Positive Revenue Forecast for JD HEALTH (06618.HK); Maintains Buy Rating with Target Price of HKD80

BofAS: JD HEALTH (06618.HK) Surpasses Quarterly Expectations; Target Price Set at $75 and Buy Rating Maintained

HSI Rises 435 Points as JD-SW Jumps 10% and JD LOGISTICS Soars 23%

HSBC Research Anticipates Continued Strong Revenue Growth for JD HEALTH (06618.HK) This Year, Raises Target Price to $80

CICC Reduces JD HEALTH's Target Price to HKD66.2, Maintains Outperform Rating

UBS: JD HEALTH Exceeds 2025 Results; Investors Should Pay Attention to 2026 Forecast

CLSA Lowers JD HEALTH's Target Price to HKD66.5, Anticipates Continued Positive Surprises in Drug Sales

M Stanley Predicts JD HEALTH (06618.HK) Will Continue Strong Growth This Year, Though Net Profit May Remain Steady

Nomura: JD Health Exceeds Last Quarter Expectations; FY26 Profit Margin Forecast Appears Cautious

HSI Starts 37 Points Up; JD.com Shows Strong Performance After Results; BYD COMPANY Sees Slight Increase

JD Health Reports Annual NP of RMB 5.375 Billion, a 29.2% Increase Year-on-Year

HSBC Research: Online Pharmacy Market Share Grows; JD HEALTH Target Price Increased to $77.5

Feb 10 2026aastocks

JD HEALTH Partners with iMEDWAY Tech to Develop AI-Driven Supply Chain Solution

Feb 08 2026aastocks

CLSA Maintains Outperform Rating for JD HEALTH (06618.HK) and Increases Earnings Projections

Feb 04 2026aastocks